| car t cell therapy penn: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| car t cell therapy penn: Praying for Emily Tom Whitehead, Kari Whitehead, Emily Whitehead, 2020-10-06 Discover the incredible true story of Emily Whitehead, the first child to receive CAR-T cell treatment for her leukemia -- and learn how her family's faith journey guided them in the fight for her life. When their five-year-old daughter was diagnosed with leukemia, Tom and Kari Whitehead's world was shattered. They vowed to do whatever it took to help their daughter, and as they made decisions about how to best treat her, Tom found his faith coming to him in whispers, guiding his decisions and keeping his hope alive, while Kari placed great faith in science and the doctors surrounding her little girl. But as Emily's condition continued to worsen, they both prayed for a miracle. Then, their miracle arrived, in the form of an experimental treatment called CAR-T cell therapy that, against all odds, saved Emily's life. Because of Emily's miraculous recovery, this treatment is now used widely to treat cancer and has gone on to save hundreds of lives and promises to help thousands more. For all the acclaim and attention this important new approach to treating cancer has received, few know the full story of all it took to make this miracle happen. In Praying for Emily, the Whiteheads share their story, recounting the belief, resilience, and support that got them through the most difficult time of their lives. |
| car t cell therapy penn: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t cell therapy penn: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| car t cell therapy penn: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car t cell therapy penn: The Gene Siddhartha Mukherjee, 2016-05-17 The #1 NEW YORK TIMES Bestseller The basis for the PBS Ken Burns Documentary The Gene: An Intimate History Now includes an excerpt from Siddhartha Mukherjee’s new book Song of the Cell! From the Pulitzer Prize–winning author of The Emperor of All Maladies—a fascinating history of the gene and “a magisterial account of how human minds have laboriously, ingeniously picked apart what makes us tick” (Elle). “Sid Mukherjee has the uncanny ability to bring together science, history, and the future in a way that is understandable and riveting, guiding us through both time and the mystery of life itself.” —Ken Burns “Dr. Siddhartha Mukherjee dazzled readers with his Pulitzer Prize-winning The Emperor of All Maladies in 2010. That achievement was evidently just a warm-up for his virtuoso performance in The Gene: An Intimate History, in which he braids science, history, and memoir into an epic with all the range and biblical thunder of Paradise Lost” (The New York Times). In this biography Mukherjee brings to life the quest to understand human heredity and its surprising influence on our lives, personalities, identities, fates, and choices. “Mukherjee expresses abstract intellectual ideas through emotional stories…[and] swaddles his medical rigor with rhapsodic tenderness, surprising vulnerability, and occasional flashes of pure poetry” (The Washington Post). Throughout, the story of Mukherjee’s own family—with its tragic and bewildering history of mental illness—reminds us of the questions that hang over our ability to translate the science of genetics from the laboratory to the real world. In riveting and dramatic prose, he describes the centuries of research and experimentation—from Aristotle and Pythagoras to Mendel and Darwin, from Boveri and Morgan to Crick, Watson and Franklin, all the way through the revolutionary twenty-first century innovators who mapped the human genome. “A fascinating and often sobering history of how humans came to understand the roles of genes in making us who we are—and what our manipulation of those genes might mean for our future” (Milwaukee Journal-Sentinel), The Gene is the revelatory and magisterial history of a scientific idea coming to life, the most crucial science of our time, intimately explained by a master. “The Gene is a book we all should read” (USA TODAY). |
| car t cell therapy penn: Biology and Treatment of Leukemia and Bone Marrow Neoplasms Vinod Pullarkat, Guido Marcucci, 2021-10-09 This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students. |
| car t cell therapy penn: Chronic Graft Versus Host Disease Georgia B. Vogelsang, Steven Z. Pavletic, 2009-04-20 Chronic graft versus host disease (GVHD) is the most common complication of allogenic bone marrow transplantation. Because of the protracted clinical course of chronic GVHD, transplant centers and hematology/oncology offices are inadequately equipped to manage these immuno-incompetent patients with a multi-system disorder. Practitioners need to be able to recognize and effectively manage chronic GVHD as a late effect of more than half of allogenic transplantations. The text is oriented for the clinician, with chapters covering staging, organ site and system-specific manifestations, treatment options, and supportive care. Drs Georgia B. Vogelsang and Steven Z. Pavletic have been pioneers in the recognition of the multi-organ complexity of this disease and have gathered the input of a variety of subspecialist physicians for this book. This book fills the gap in practical literature on chronic GVHD, providing a comprehensive, up-to-date, and clinically relevant resource for anyone who deals with cancer patients post-transplant. |
| car t cell therapy penn: Everybody Wants to Go to Heaven but Nobody Wants to Die: Bioethics and the Transformation of Health Care in America Amy Gutmann, Jonathan D. Moreno, 2019-08-27 NOW FEATURING A NEW AFTERWORD, PANDEMIC ETHICS From two eminent scholars comes a provocative examination of bioethics and our culture’s obsession with having it all without paying the price. Shockingly, the United States has among the lowest life expectancies and highest infant mortality rates of any high-income nation, yet, as Amy Gutmann and Jonathan D. Moreno show, we spend twice as much per capita on medical care without insuring everyone. A “remarkable, highly readable journey” (Judy Woodruff ) sure to become a classic on bioethics, Everybody Wants to Go to Heaven but Nobody Wants to Die explores the troubling contradictions between expanding medical research and neglecting human rights, from testing anthrax vaccines on children to using brain science for marketing campaigns. Providing “a clear and compassionate presentation” (Library Journal) of such complex topics as radical changes in doctor-patient relations, legal controversies over in vitro babies, experiments on humans, unaffordable new drugs, and limited access to hospice care, this urgent and incisive history is “required reading for anyone with a heartbeat” (Andrea Mitchell). |
| car t cell therapy penn: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| car t cell therapy penn: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t cell therapy penn: Immunology of Inflammation Peter A. Ward, 1983 |
| car t cell therapy penn: The Duke Glioma Handbook Allan H. Friedman, 2016-03-31 Provides a summary of glioma biology, genetics and management, based on the world-leading Duke University Preston Robert Tisch Brain Tumor Center program. |
| car t cell therapy penn: Advances in childhood leukemia , 1982 |
| car t cell therapy penn: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t cell therapy penn: A New Deal for Cancer Abbe R. Gluck, Charles S Fuchs, 2021-11-16 An unprecedented constellation of experts—leading cancer doctors, policymakers, cutting-edge researchers, national advocates, and more—explore the legacy and the shortcomings from the fifty-year war on cancer and look ahead to the future. The longest war in the modern era, longer than the Cold War, has been the war on cancer. Cancer is a complex, evasive enemy, and there was no quick victory in the fight against it. But the battle has been a monumental test of medical and scientific research and fundraising acumen, as well as a moral and ethical challenge to the entire system of medicine. In A New Deal for Cancer, some of today’s leading thinkers, activists, and medical visionaries describe the many successes in the long war and the ways in which our deeper failings as a society have held us back from a more complete success. Together they present an unrivaled and nearly complete map of the battlefield across dimensions of science, government, equity, business, the patient provider experience, and more, documenting our emerging understanding of cancer’s many unique dimensions and offering bold new plans to enable the American health care system to deliver progress and hope to all patients. |
| car t cell therapy penn: Inheriting Possibility Ezekiel J. Dixon-Román, 2017-08-01 How has the dominant social scientific paradigm limited our understanding of the impact of inherited economic resources, social privilege, and sociocultural practices on multigenerational inequality? In what ways might multiple forces of social difference haunt quantitative measurements of ability such as the SAT? Building on new materialist philosophy, Inheriting Possibility rethinks methods of quantification and theories of social reproduction in education, demonstrating that test performance results and parenting practices convey the impact of materially and historically contingent patterns of differential possibility. Ezekiel J. Dixon-Román explores the dualism of nature and culture that has undergirded theories of inheritance, social reproduction, and human learning and development. Research and debate on the reproduction of power relations have rested on a premise that nature is made up of fixed universals on which the creative, intellective, and discursive play of culture are based. Drawing on recent work in the physical and biological sciences, Dixon-Román argues that nature is culture. He contends that by assuming a rigid nature/culture binary, we ultimately limit our understanding of how power relations are reproduced. Through innovative analyses of empirical data and cultural artifacts, Dixon-Román boldly reconsiders how we conceptualize the processes of inheritance and approach social inquiry in order to profoundly sharpen understanding and address the reproducing forces of inequality. |
| car t cell therapy penn: Childhood Cancer Survivors Nancy Keene, Wendy Hobbie, Kathy Ruccione, 2014-03-01 More than 325,000 children, teens, and adults in the United States are survivors of childhood cancer. The surgery, radiation, chemotherapy, and stem cell transplants used to cure children can affect growing bodies and developing minds. If survivors know of these potential problems, they can take steps to identify, cope with, or treat them early if they do develop. The third edition of Childhood Cancer Survivors charts the territory for survivors by providing state-of-the-art information about: Medical late effects from treatment Emotional aspects of surviving cancer Schedules for follow-up care Challenges in the heath-care system Lifestyle choices to maximize health Discrimination in employment or insurance Woven throughout the text are stories from more than 100 survivors and parents. Authors Keene, Hobbie, and Ruccione are experts in the field of childhood cancer. Keene is the mother of a survivor of childhood leukemia and the author of several books including Childhood Leukemia, Childhood Cancer, Educating the Child with Cancer, and Chemo, Craziness & Comfort. Hobbie is Associate Director of the Cancer Survivorship Program at Children's Hospital of Philadelphia. Ruccione is Co-Director of the HOPE (Hematology-Oncology Psychosocial and Education) Program in the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles. |
| car t cell therapy penn: Successes and Challenges of NK Immunotherapy Benjamin Bonavida, Anahid Jewett, 2021-06-23 Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells. Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers. - Discusses the unique developmental applications of NK immunotherapy against cancers, which differs greatly from other types of immunotherapies - Provides up-to-date and highly relevant information through chapters written by the leading researchers in the field - Presents a significant number of schematic diagrams for easy understanding and reproducibility |
| car t cell therapy penn: A Shot to Save the World Gregory Zuckerman, 2021-10-26 An inspiring and informative page-turner. –Walter Isaacson Longlisted for the FT/McKinsey Business Book of the Year Award The authoritative account of the race to produce the vaccines that are saving us all, from the #1 New York Times bestselling author of The Man Who Solved the Market Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world’s biggest drug and vaccine makers were slow to react or couldn’t muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life’s work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. A #1 New York Times bestselling author and award-winning Wall Street Journal investigative journalist lauded for his “bravura storytelling” (Gary Shteyngart) and “first-rate” reporting (The New York Times), Zuckerman takes us inside the top-secret laboratories, corporate clashes, and high-stakes government negotiations that led to effective shots. Deeply reported and endlessly gripping, this is a dazzling, blow-by-blow chronicle of the most consequential scientific breakthrough of our time. It’s a story of courage, genius, and heroism. It’s also a tale of heated rivalries, unbridled ambitions, crippling insecurities, and unexpected drama. A Shot to Save the World is the story of how science saved the world. |
| car t cell therapy penn: Childhood Cancer and Functional Impacts Across the Care Continuum National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Childhood Cancers and Disability, 2021-09-09 Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas. |
| car t cell therapy penn: Baboon Metaphysics Dorothy L. Cheney, Robert M. Seyfarth, 2008-09-15 Animals. |
| car t cell therapy penn: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| car t cell therapy penn: The Domestic Dog James Serpell, 1995 A scientific analysis of dogs, their behaviour, and their relationships with humans. |
| car t cell therapy penn: STOP, THAT and One Hundred Other Sleep Scales Azmeh Shahid, Kate Wilkinson, Shai Marcu, Colin M Shapiro, 2012-01-06 There are at least four reasons why a sleep clinician should be familiar with rating scales that evaluate different facets of sleep. First, the use of scales facilitates a quick and accurate assessment of a complex clinical problem. In three or four minutes (the time to review ten standard scales), a clinician can come to a broad understanding of the patient in question. For example, a selection of scales might indicate that an individual is sleepy but not fatigued; lacking alertness with no insomnia; presenting with no symptoms of narcolepsy or restless legs but showing clear features of apnea; exhibiting depression and a history of significant alcohol problems. This information can be used to direct the consultation to those issues perceived as most relevant, and can even provide a springboard for explaining the benefits of certain treatment approaches or the potential corollaries of allowing the status quo to continue. Second, rating scales can provide a clinician with an enhanced vocabulary or language, improving his or her understanding of each patient. In the case of the sleep specialist, a scale can help him to distinguish fatigue from sleepiness in a patient, or elucidate the differences between sleepiness and alertness (which is not merely the inverse of the former). Sleep scales are developed by researchers and clinicians who have spent years in their field, carefully honing their preferred methods for assessing certain brain states or characteristic features of a condition. Thus, scales provide clinicians with a repertoire of questions, allowing them to draw upon the extensive experience of their colleagues when attempting to tease apart nuanced problems. Third, some scales are helpful for tracking a patient’s progress. A particular patient may not remember how alert he felt on a series of different stimulant medications. Scale assessments administered periodically over the course of treatment provide an objective record of the intervention, allowing the clinician to examine and possibly reassess her approach to the patient. Finally, for individuals conducting a double-blind crossover trial or a straightforward clinical practice audit, those who are interested in research will find that their own clinics become a source of great discovery. Scales provide standardized measures that allow colleagues across cities and countries to coordinate their practices. They enable the replication of previous studies and facilitate the organization and dissemination of new research in a way that is accessible and rapid. As the emphasis placed on evidence-based care grows, a clinician’s ability to assess his or her own practice and its relation to the wider medical community becomes invaluable. Scales make this kind of standardization possible, just as they enable the research efforts that help to formulate those standards. The majority of Rating Scales in Sleep and Sleep Disorders:100 Scales for Clinical Practice is devoted to briefly discussing individual scales. When possible, an example of the scale is provided so that readers may gain a sense of the instrument’s content. Groundbreaking and the first of its kind to conceptualize and organize the essential scales used in sleep medicine, Rating Scales in Sleep and Sleep Disorders:100 Scales for Clinical Practice is an invaluable resource for all clinicians and researchers interested in sleep disorders. |
| car t cell therapy penn: Human Caring Science Jean Watson, 2012 Rev. ed. of: Nursing: human science and human care / Jean Watson. c1999. |
| car t cell therapy penn: Head & Neck Endocrine Surgery David Goldenberg, 2021-07-28 The quintessential reference on surgical and medical management of thyroid and parathyroid Head & Neck Endocrine Surgery: A Comprehensive Textbook, Surgical, and Video Atlas by renowned head and neck surgical oncologist David Goldenberg, with chapters by esteemed contributors from various fields, is the most comprehensive textbook written on this topic to date. It covers all aspects of medical and surgical management of thyroid and parathyroid disease. In addition to classic and cutting-edge surgical procedures, the text discusses novel topics such as molecular testing, radiofrequency ablation of thyroid nodules, risk stratification, pathology, and remote access surgical techniques. The book is organized in seven sections and 62 succinct chapters featuring a unique layout conducive to modern learning. Five sections on the thyroid gland start with historical perspectives and basic science, concluding with postoperative management and therapies including ethical and medicolegal concerns. The last two sections focus on historical perspectives, basic science, and surgical management of parathyroid diseases. Key Highlights Well-illustrated high-yield case studies, key points, pearls, points to ponder, and annotated bibliographies noting the top references enhance acquisition of knowledge The text encompasses a full spectrum of thyroid and parathyroid diseases 29 narrated high-quality videos provide nuanced insights about physical appearance not realized solely from intraoperative photographs or illustrations This is an essential resource for otolaryngologists–head and neck surgeons, endocrine surgeons, general surgeons, endocrinologists, residents, fellows, and allied health personnel. |
| car t cell therapy penn: Academic Entrepreneurship for Medical and Health Scientists Nalaka Gooneratne, Rachel McGarrigle, Flaura Winston, 2020-06 The recent momentum and urgency around translating science and technology into health innovation is inspiring. It is transforming academia, too, as the rapidly-evolving world of health innovation has given rise to a new breed of academic - the academic entrepreneur - who works to move ideas from initial research to practical implementation. The work of these individuals is crucial to realizing the potential of investments in better care, and yet there existed no central repository for information and wisdom relevant to their mission; no place to house and explore the evolving knowledge base around translating evidence into impact.We aim to build one. In the spirit of collaboration, the Children's Hospital of Philadelphia (CHOP) Research Institute collaborated with the University of Pennsylvania's (Penn) Institute for Translational Medicine and Therapeutics (ITMAT) to seed fund a grassroots effort of editors, subject matter experts, and translational research students to create a free open education resource stored on ScholarlyCommons (University of Pennsylvania, Philadelphia, PA).Academic Entrepreneurship seeks to build a diverse community of empowered professionals who know how to bridge the worlds of academic research and commercialization to turn ideas and discoveries into innovations that provide value to patients, providers, and healthcare systems, thereby realizing full market potential and societal impact. This book is a repository of tools, advice, and best practices that establishes a foundation for academic researchers and innovators wherever they may reside.Recognizing that academic entrepreneurs are busy and bright, and have limited time to learn entrepreneurship, the chapters in this book were designed as an efficient and state-of-the-art source of guidance. With carefully curated content as a strong foundation, the reader will have quick introductions to key topics in academic entrepreneurship and innovations with a list of resources for those who wish to go further.This book was created as a limited print run of the first edition of the living content stored in the University of Pennsylvania's open access repository, ScholarlyCommons, as of 1/1/2020. As a living e-textbook, the content of Academic Entrepreneurship for Medical and Health Scientists is continuously enhanced and revised. |
| car t cell therapy penn: Inpatient Dermatology Misha Rosenbach, Karolyn A. Wanat, Robert G. Micheletti, Laura A. Taylor, 2018-11-03 Inpatient Dermatology is a concise and portable resource that synthesizes the most essential material to help physicians with recognition, differential diagnosis, work-up, and treatment of dermatologic issues in the hospitalized patient. Complete with hundreds of clinical and pathologic images, this volume is both an inpatient dermatology atlas and a practical guide to day-one, initial work-up, and management plan for common and rare skin diseases that occur in the inpatient setting. Each chapter is a bulleted, easy-to-read reference that focuses on one specific inpatient dermatologic condition, with carefully curated clinical photographs and corresponding histopathologic images to aid readers in developing clinical-pathologic correlation for the dermatologic diseases encountered in the hospital. Before each subsection the editors share diagnostic pearls, explaining their approach to these challenging conditions. This book is structured to be useful to physicians, residents, and medical students. It spans dermatology, emergency medicine, internal medicine, infectious disease, and rheumatology. Inpatient Dermatology is the go-to guide for hospital-based skin diseases, making even the most complex inpatient dermatologic issues approachable and understandable for any clinician. |
| car t cell therapy penn: The Emperor of All Maladies Siddhartha Mukherjee, 2011-08-09 Winner of the Pulitzer Prize and a documentary from Ken Burns on PBS, this New York Times bestseller is “an extraordinary achievement” (The New Yorker)—a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence. Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with—and perished from—for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out “war against cancer.” The book reads like a literary thriller with cancer as the protagonist. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer. |
| car t cell therapy penn: Progress in Clinical and Biological Research George J. Brewer, 1975 |
| car t cell therapy penn: Second Generation Cell and Gene-Based Therapies Alain Vertes, Nathan J. Dowden, Devyn Smith, Nasib Qureshi, 2020-02-07 Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic science, clinical therapy, technology development, and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines, is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths, which will ultimately facilitate clinical delivery of cutting edge curative products.The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals. - Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization - Perspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insights - Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies |
| car t cell therapy penn: The Last Lecture Randy Pausch, Jeffrey Zaslow, 2010 The author, a computer science professor diagnosed with terminal cancer, explores his life, the lessons that he has learned, how he has worked to achieve his childhood dreams, and the effect of his diagnosis on him and his family. |
| car t cell therapy penn: Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist Valerie I. Brown, 2017-12-22 This volume provides a comprehensive and state-of-the-art review on pediatric hematopoietic stem cell transplantation (HSCT). The book covers such topics as graft versus host disease (GVHD), HSC mobilization, stem cell selection, and HSCT-relevant laboratory assays and techniques. The text is specially formatted so that the scientific basis of HSCT and ethical considerations are integrated into the relevant clinical framework. Each chapter also includes diagrams, illustrations, and tables that summarize key points and concepts that can be used as a quick visual reference for the reader. Written by experts in the field, Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist is a valuable resource on pediatric HSCT suited for pediatric hematologists-oncologists, fellows, advanced practitioners, clinical nurses, and other referring physicians. |
| car t cell therapy penn: Bittersweet Chris Feudtner, 2004-01-21 One of medicine's most remarkable therapeutic triumphs was the discovery of insulin in 1921. The drug produced astonishing results, rescuing children and adults from the deadly grip of diabetes. But as Chris Feudtner demonstrates, the subsequent transformation of the disease from a fatal condition into a chronic illness is a story of success tinged with irony, a revealing saga that illuminates the complex human consequences of medical intervention. Bittersweet chronicles this history of diabetes through the compelling perspectives of people who lived with this disease. Drawing on a remarkable body of letters exchanged between patients or their parents and Dr. Elliot P. Joslin and the staff of physicians at his famed Boston clinic, Feudtner examines the experience of living with diabetes across the twentieth century, highlighting changes in treatment and their profound effects on patients' lives. Although focused on juvenile-onset, or Type 1, diabetes, the themes explored in Bittersweet have implications for our understanding of adult-onset, or Type 2, diabetes, as well as a host of other diseases that, thanks to drugs or medical advances, are being transformed from acute to chronic conditions. Indeed, the tale of diabetes in the post-insulin era provides an ideal opportunity for exploring the larger questions of how medicine changes our lives. |
| car t cell therapy penn: Tumor Dormancy and Recurrence Yuzhuo Wang, Francesco Crea, 2017-09-11 This volume will be the first to provide a comprehensive description of tumor dormancy. It will define the clinical and biological aspects of this phenomenon, as well as the cellular and molecular mechanisms associated with tumor dormancy. Chapters will be authored by world-renewed experts who are conducting cutting-edge research in the field. A unique feature will be a conclusive paragraph detailing future development and foreseeable clinical applications at the end of each chapter. The volume will serve as a fundamental instrument for every researcher and clinician interested in the field of tumor dormancy as well as a means of disseminating stimulating concepts and prompting the development of innovative technological solutions. |
| car t cell therapy penn: Health Law and Bioethics Joan H. Krause, Richard S. Saver, Robin Fretwell Wilson, 2009-03-12 A unique offering in this field from a sterling author team, Health Law and Bioethics: Cases in Context presents the stories and context of landmark cases in the field. By conveying back story and creating context, this brief text hooks students’ interest and deepens their understanding of the law and policy implications of each case. |
| car t cell therapy penn: The Penn Dental Journal , 1898 |
| car t cell therapy penn: Immunotherapy for Gastrointestinal Malignancies Ramakrishna Vadde, Ganji Purnachandra Nagaraju, 2022-02-15 This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies. |
| car t cell therapy penn: Importing Into the United States U. S. Customs and Border Protection, 2015-10-12 Explains process of importing goods into the U.S., including informed compliance, invoices, duty assessments, classification and value, marking requirements, etc. |
Chimeric Antigen Receptor T-Cell Therapy Current Perspective …
Here, we review the core structure of the CAR, the evolution of different CAR generations, CAR T-cell therapy limitations, and current strategies being investigated to over-come the T …
Building the “On-Ramp” for Cell Therapy Clinical Adoption
Apr 19, 2023 · Cell Therapy & Transplant | Penn Medicine Operational Summary Why 26 pages? • The document fuses, from identification to post 30 days infusion, how the center will …
EXCLUSIVE LICENSING OF CDH17 CAR T CELL THERAPY FROM …
Chimeric exclusive license to novel 3rdgeneration CDH17 CAR T from world leading cell therapy centre, the University of Pennsylvania (Penn) Phase 1 Trial 2022.
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for …
Oct 14, 2019 · ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy relies on the ex vivo manipulation of patient T cells to create potent, cancer-targeting therapies, shown to be …
Penn discovers new, rare mechanism for ALL to relapse after …
New research from the Abramson Cancer Center of the University of Pennsylvania found that in one patient, the CAR lentivirus that would usually enter a T cell to teach it to hunt cancer...
CAR T cell Therapy for CNS Involvement and Down Syndrome
CAR T cells can induce durable CNS remissions in pts with relapsed and/or refractory B ALL with CNS involvement. The risk of severe CRS and infectious complications in the acute period …
Deletion of the inhibitory co-receptor CTLA-4 enhances and
CD19-directed CAR T cell therapy is an effective treatment for B cell malignancies, but some patients fail to respond. Agarwal et al. demonstrate that deletion of enhances anti-tumor. …
CAR T-Cell Therapy for Your Patients: What You Need To Know
• Describe the MOA of Chimeric Antigen Receptor T-cell (CAR-T) therapy and approved-FDA indications • Understand where CAR-T therapy might fit into the cancer care landscape and its …
Current understanding and management of CAR T cell …
Chimeric antigen receptor (CAR) T cell therapy, a form of T cell redi-rection therapy involving ex vivo engineering of T cells to express a transgenic CAR targeting a specific...
Secondary cancers following CAR T cell therapy are rare, …
CAR T cell therapy, a personalized form of immunotherapy in which each patient's T cells are modified to target and kill their cancer cells, was pioneered at Penn.
Phase I study of autologous T cells bearing fully-humanized …
Determine the safety and feasibility of intravenous administration and local delivery of lentiviral transduced huCART-meso cells, with and without lymphodepleting chemotherapy in the target …
Tragedy, Perseverance, and Chance The Story of CAR-T Therapy
In August 2017, the FDA approved the first chi-meric antigen receptor T-cell (CAR-T) therapy, Novartis’s tisa-genlecleucel, which uses the Penn-developed technology, for patients up to 25 …
Cell Therapy and Transplant (CTT) Program CARs Cruising …
‣CAR T during COVID (at Penn) • Exclusively treated OP during pandemic (March-August) – Curative intent and one treatment allowed the program to continue during pandemic – Penn …
CAR T cell combination therapies to treat cancer - Cell Press
Chimeric antigen receptor (CAR) T cell therapy utilizes engineered T cells to target specific tumor antigens, demon-strating high efficacy and gaining FDA approval in some hematological malig …
Danaher Partners with the University of Pennsylvania's Center …
Mar 7, 2023 · We are delighted to be partnering with the CAR T pioneers at Penn and believe that combining our expertise in science and technology will help bring the next generation of cell …
Study of decade-long leukemia remissions after Car T reveals …
Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children's Hospital of Philadelphia explains the longest persistence of CAR T …
CAR-T Therapy: What Does it Mean for Pathologists?
Explain the science behind the development of chimeric antigen receptor T-cells (CAR-T) cells and the clinical utility of CAR-T in hematopoietic malignancies. List three possible adverse …
Cellicon Valley '23: The Future of Cell and Gene Therapies
As home to the first FDA-approved cell and gene therapies, Penn Medicine and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into …
TnMUC1-targetedCAR T cells - Perelman School of Medicine …
‣TnMUC1 is an attractive target for CAR T cell therapy in solid malignancies ‣The 5E5 monoclonal antibody against TnMUC1 has specificity for TnMUC1+ tumor cells and limited binding to the …
Pricing Tolerance & the Evolution of Cell Therapy Costs of Care
May 6, 2021 · CAR-T has the outcomes paradox of mixing cure and Progressive R/R disease. The innovative gene therapy, called Zolgensma, has a reported list price of £1.79 million ($2.48 …
Jacqueline Plesset
from CAR T cell therapy and other immunotherapies. Notably, T cell inflamed tumors in mouse models have also shown sensitivity to immune checkpoint blockade targeting CTLA4 and PD1 …
ringing AR T ell Therap y to the loodless Medicine ommunity …
Melanie Cole, MS (Host): Welcome to the podcast series from the specialists at Penn Medicine. I'm Melanie ole and joining me today is Dr. Patricia Ford. She's the Director of the ellular …
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large …
Advanced Medicine, University of Penn-sylvania, 3400 Civic Center Blvd., Philadel - phia, PA 19104, or at stephen .schuster@ ... (CAR) T-cell therapy tisagenlecleucel (formerly CTL019) …
ADVANCES IN CAR T-CELL THERAPY - Leukemia
Dec 15, 2020 · CAR T-cell therapy is a type of cancer therapy that uses a patient’s own modified white blood cells to kill cancer cells. 6 ... Maude et al. NEJM 2018 PENN 4-1BB ALL …
PATIENT & CAREGIVER EDUCATION CAR T Cell Therapy: A …
Feb 27, 2025 · Figure 2. CAR T cell attaching to cancer cell Understanding your autologous CAR T cell therapy Autologous (aw-TAH-luh-gus) means something taken from your own body, …
U.S. Authorized Treatment Centers for CAR T-Cell Therapy
• Penn Medicine Abramson Cancer Center • Penn State Cancer Institute • Sidney Kimmel Cancer Center - Jefferson Health • UPMC Hillman Cancer Center South Carolina • MUSC Health …
AETNA BETTER HEALTH®
Hypogammaglobulinemia from chimeric antigen receptor T (CAR-T) therapy 25. Multiple myeloma 26. Neonatal hemochromatosis, prophylaxis 27. Opsoclonus-myoclonus ... pulmonary therapy, …
CAR T-Cell Therapy for Your Patients: What You Need To …
Penn Scale Mild reaction Moderate reaction Requires IV therapies; some signs of organ dysfunction (grade 2 Cr or grade 3 LFTs) Hospitalization for ... or older with CRS that occurs …
Regulatory Considerations to Accelerate Cell & Gene Therapy …
Cell & Gene Therapy Development Jiwen Zhang, Ph.D. Cellicon Valley 2021, May 6, 2021. 2 ... • Spain: AEMPS authorises Hospital Clínic's CAR-T ARI-0001 for patients with acute …
Payer Perspectives on Gene Therapy Reimbursement - Real …
2017 as the initial chimeric antigen receptor (CAR) T-cell therapies, Kymriah (tisagenlecleucel/Novartis) and Yescarta (axicabtagene ciloleucel/Kite Pharma) were being …
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large …
Dec 1, 2018 · Advanced Medicine, University of Penn-sylvania, 3400 Civic Center Blvd., Philadel - phia, PA 19104, or at stephen .schuster@ ... (CAR) T-cell therapy tisagenlecleucel (formerly …
FRPT 2023 3rd FLASH Radiotherapy and Particle Therapy …
“COMBINATION OF FLASH RADIATION WITH CAR T CELL IMMUNOTHERAPY FOR BRAIN TUMOR” Session Type: Late-breaking Abstracts Session Name: 0830 - ORAL …
The Economics of CAR T-Cell Therapy - accc-cancer.org
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing area of oncology that has been transforming cancer care since its initial approval for acute lymphoblastic leukemia in …
CAR-T Treatment Centers for B-cell Lymphomas
V: 0/2023 CAR-T Treatment Centers for B-cell Lymphomas Therapy Offered: Axi-cel (Yescarta®) Tisa-cel (Kymriah®) Brexu-cel (Tecartus®) Liso-cel (Breyanzi®) Florida JOHNS HOPKINS …
SE19009 - Chimeric Antigen Receptor (CAR) T-Cell Therapy …
Mar 17, 2022 · for CAR T-Cell Therapy. MLN Matters Special Edition (SE) article SE19009 replaces those instructions. Please make sure your billing staffs are aware of these updated …
Mechanisms of cytokine release syndrome and neurotoxicity …
Since CAR T-cell-related toxicities are investigated mostly in the eld of hematological malignances, they are the focus of this review. Current understanding of the mechanisms of …
CAR-T Treatment Centers for B-cell Lymphomas
CAR-T Treatment Centers for B-cell Lymphomas Therapy Offered: Axi-cel (Yescarta®) Tisa-cel (Kymriah®) Brexu-cel (Tecartus®) Liso-cel (Breyanzi®) California V3: 9/22/2022 UCSF …
CAR-T cell therapy for hematological malignancies: History, …
Jul 8, 2023 · 2.1. First-generation CAR-T cell therapy The first-generation CAR-T cells were developed in the late 1980s and early 1990s and represent the earliest form of CAR T cell …
Considerations for the Development of Chimeric Antigen …
Chimeric antigen receptor (CAR) T cell products are human gene therapy. 1. products in which the T cell specificity is genetically modified to enable recognition of a desired target antigen for
Chimeric antigen receptor T-cell (CAR-T) therapy
What is CAR-T therapy? CAR-T therapy is a treatment that uses your own immune system to destroy cancer cells. Why do I need CAR-T therapy? In the UK, CAR-T therapy is currently …
CAR T Cell Therapy: A Game Changer in Cancer Treatment
CAR T Cell Therapy: A Game Changer in Cancer Treatment HildeAlmåsbak, 1 TanjaAarvak, 1 andMohanC.Vemuri 2 Cellular Medicine, Bioproduction,er mo Fisher Scientic, Oslo, Norway ...
Induction of resistance to chimeric antigen receptor T cell …
BRIEF COMMUNICATION https/doi.org10.103s41591-01-0201-9 1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, …
Discontinuation of Transmission-Based Precautions for COVID …
Dec 19, 2020 · correspondence reported that some severely immunocompromised patients receiving CAR-T cell therapy or allogeneic stem cell transplants for hematologic malignancies …
Toxicity management after chimeric antigen receptor T cell …
CAR T cell products14, and thus the threshold for corticosteroid use will vary based on the product used and patient population. Finally, our experience is that anti-IL -6 therapy is often
Clinical Trials in Neuroendocrine Tumors - Perelman School of …
Trials in Development at Penn Phase I CAR-T trial in pancreatic neuroendocrine tumors and neuroendocrine tumors of the GI tract Phase II trial of PARP inhibition and immunotherapy in …
Súčasné indikácie CAR T-bunkovej liečby - solen.sk
of CAR T-cell therapy, essential examinations before approval of the indication and administration of CAR T-cell as well as prognostic factors supporting an optimal selection of patients suitable …
Human T Cell Subsets and Their Clinical Applications for …
T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy Derek Lee 1,2 , Carl J. Rosenthal 3 , Natalie E. Penn 1 , Zachary Spencer Dunn 1,4 , Yang Zhou 1,2
CAR T-cell therapy - UZ Leuven
CAR T-cell therapy 11 Specific side effects The CAR T-cells go to work after the infusion. Any remaining cancer tissue will stimulate the CAR T-cells, allowing them to multiply and destroy …
Review of CAR-T cell therapy for the WHO Model List of …
CAR-T cell therapy is used as third-line treatment for relapsed or refractory (r/r) DLBCL (3, 4). 7. Review of efficacy and safety Summary of the methodological approach We are developing a …
FDA Briefing Document Oncologic Drugs Advisory Committee …
bla 125646 tisagenlecleucel . 5 . a. bbreviations. g. lossary. ae adverse event. aesi adverse event of special interest. alc absolute lymphocte count. all a. cute . l ...
Emerging frontiers in adoptive cell therapies: innovations
49. Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma, NCT04134325, 2019. 50. CART-EGFRvIII + Pembrolizumab in GBM, …
Presentation Slides CAR T-Cell - Leukemia & Lymphoma …
í î l í ñ l î ì î ì ï ñ t Z ] Z d r o o Z Ç M Z d r o o Z Ç ] Ç } ( v Z Ç Z µ
CAR T-Cell Therapy - University of Utah
Sep 18, 2024 · CAR T-Cell Infusion •CAR T-cell infusion generally occurs in the outpatient BMT room. •Prior to your infusion, your care team will give you pre-medications. •There is a risk of …
Bringing CAR T–Cell Therapies to Community Oncology
therapy. Reimbursement for CAR T-cell therapy is typically less than the costs incurred for providing it, although strides have been made to ease this financial burden. When it was first …
CAR-T 細胞療法の歴史と展望 - J-STAGE
modified with the chimeric antigen receptor (CAR) gene. CD19-targeted CAR-T cell therapy (tisagenlecleucel) has shown dramatic treatment results in patients with relapsed and …
Cancer Support Community
%PDF-1.6 %âãÏÓ 9607 0 obj > endobj 9625 0 obj >/Filter/FlateDecode/ID[88AA691A62C04732BD73E7C5F4CDDFED>]/Index[9607 27]/Info …
TCR-T免疫治疗肿瘤:现状、挑战及展望
[Abstract] Engineered T cell receptor-T cell (TCR-T) therapy and chimeric antigen receptor-T cell (CAR-T) therapy are currently the two most effective ways of adoptive T cell therapy. Because …
Clinical manufacturing of CAR T cells: foundation of a …
Adoptive cell therapy using naturally occurring endogenous tumor-infiltrating lymphocytes or T cells genetically engineered to express either T-cell receptors1 or chimeric antigen receptors …
CAR T-Cell Therapy in Action: Successful Examples in …
CAR T-cell therapy process (similar to starting an inpatient program), but with extra considerations for outpatient use. To facilitate appropriate selection of outpatient candidates, City of Hope …
Patient Information Leaflet for Chimeric Antigen Receptor …
effector cell therapy”. Chimeric antigen receptor (CAR) T cell therapy is a novel treatment for some types of cancers. It is a form of immunotherapy, a type of treatment that helps your …
CAR-T cell manufacturing landscape-Lessons from the past …
expanded until therapeutic CAR-T cell doses are achieved. This gen-eral protocol has been employed with minor modifications over the last decade for hundreds of clinical trials, as well …
Evolving patterns of transplant strategies for mantle cell …
BTK inhibitors and CAR-T therapy. ... Background: Mantle cell lymphoma is an aggressive lymphoma with poor survival after che-motherapy alone. Both autologous (auto) and …
Chimeric Antigen Receptor T-Cell (CAR T) Therapy
Chimeric antigen receptor (CAR) T-cell therapy is an adoptive T-cell therapy that uses engineered T cells from a patient’s own immune system to attack cancer cells by targeting proteins …
Patient-derived glioblastoma organoids as real-time ... - Cell …
Dec 9, 2024 · avatars for assessing responses to clinical CAR-T cell therapy Graphical abstract Highlights d Rapid GBO generation in a phase 1 clinical trial for real-time treatment …
Distinct Signaling of Coreceptors Regulates Specific …
Feb 16, 2016 · (E) Mesothelin CAR T cell growth of bulk CD8+ T cells (left) or naive (CD45RO-CD62L+CD8+) T cells (right). CAR T cells were stimulated with beads coated with mesothelin …
Pretreatment with IL-15 and IL-18 rescues natural killer cells …
Non Cryo Cryo 0 20 40 60 80 100 %Viability 0.1519 24 48 72 0 20 40 60 80 100 120 140 Hours after thaw %Recovery Non Cryo Cryo 0 20 40 60 80 100 %CD56+CD107+NK cells 0.0270 0 6 …
Synthetic manipulation of the cancer-immunity cycle: CAR-T …
Review Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy Nathan Singh1 ,*and Marcela V. Maus2 1Division of Oncology, Washington University in St Louis School of …
Improved Expansion and In Vivo Function of Patient T Cells
about how T cell metabolism affects T cell function.27–29 Glucose, glutamine, and serine are essential nutrients for T cell expansion and function.30–32 Metal ions (e.g., Ca 2+and Zn ) are …
